212 related articles for article (PubMed ID: 10074167)
21. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency.
Zhang L; Pagano JS
Mol Cell Biol; 1997 Oct; 17(10):5748-57. PubMed ID: 9315633
[TBL] [Abstract][Full Text] [Related]
22. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1.
Ling PD; Hsieh JJ; Ruf IK; Rawlins DR; Hayward SD
J Virol; 1994 Sep; 68(9):5375-83. PubMed ID: 8057421
[TBL] [Abstract][Full Text] [Related]
23. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.
Schaefer BC; Strominger JL; Speck SH
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10565-9. PubMed ID: 7479841
[TBL] [Abstract][Full Text] [Related]
24. Methylation of the EBV genome and establishment of restricted latency in low-passage EBV-infected 293 epithelial cells.
Paulson EJ; Fingeroth JD; Yates JL; Speck SH
Virology; 2002 Jul; 299(1):109-21. PubMed ID: 12167346
[TBL] [Abstract][Full Text] [Related]
25. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas.
Xu ZG; Iwatsuki K; Oyama N; Ohtsuka M; Satoh M; Kikuchi S; Akiba H; Kaneko F
Br J Cancer; 2001 Apr; 84(7):920-5. PubMed ID: 11286472
[TBL] [Abstract][Full Text] [Related]
26. HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.
Dheekollu J; Wiedmer A; Sentana-Lledo D; Cassel J; Messick T; Lieberman PM
J Virol; 2016 Jun; 90(11):5353-5367. PubMed ID: 27009953
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain.
Nitsche F; Bell A; Rickinson A
J Virol; 1997 Sep; 71(9):6619-28. PubMed ID: 9261384
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells.
Sugiura M; Imai S; Tokunaga M; Koizumi S; Uchizawa M; Okamoto K; Osato T
Br J Cancer; 1996 Aug; 74(4):625-31. PubMed ID: 8761381
[TBL] [Abstract][Full Text] [Related]
29. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Lear AL; Rowe M; Kurilla MG; Lee S; Henderson S; Kieff E; Rickinson AB
J Virol; 1992 Dec; 66(12):7461-8. PubMed ID: 1331531
[TBL] [Abstract][Full Text] [Related]
30. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus.
Lee MA; Diamond ME; Yates JL
J Virol; 1999 Apr; 73(4):2974-82. PubMed ID: 10074147
[TBL] [Abstract][Full Text] [Related]
31. High-resolution analysis of CpG methylation and in vivo protein-DNA interactions at the alternative Epstein-Barr virus latency promoters Qp and Cp in the nasopharyngeal carcinoma cell line C666-1.
Bakos A; Banati F; Koroknai A; Takacs M; Salamon D; Minarovits-Kormuta S; Schwarzmann F; Wolf H; Niller HH; Minarovits J
Virus Genes; 2007 Oct; 35(2):195-202. PubMed ID: 17510783
[TBL] [Abstract][Full Text] [Related]
32. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines.
Schaefer BC; Strominger JL; Speck SH
J Virol; 1995 Aug; 69(8):5039-47. PubMed ID: 7609074
[TBL] [Abstract][Full Text] [Related]
33. EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Chen A; Zhao B; Kieff E; Aster JC; Wang F
J Virol; 2006 Oct; 80(20):10139-50. PubMed ID: 17005691
[TBL] [Abstract][Full Text] [Related]
34. DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines.
Sauder C; Haiss P; Grässer FA; Zimber-Strobl U; Mueller-Lantzsch N
J Gen Virol; 1994 Nov; 75 ( Pt 11)():3067-79. PubMed ID: 7964616
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus latency switch in human B-cells: a physico-chemical model.
Werner M; Ernberg I; Zou J; Almqvist J; Aurell E
BMC Syst Biol; 2007 Aug; 1():40. PubMed ID: 17764547
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays.
Inman GJ; Farrell PJ
J Gen Virol; 1995 Sep; 76 ( Pt 9)():2141-9. PubMed ID: 7561751
[TBL] [Abstract][Full Text] [Related]
37. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.
Sample J; Henson EB; Sample C
J Virol; 1992 Aug; 66(8):4654-61. PubMed ID: 1321268
[TBL] [Abstract][Full Text] [Related]
38. Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation.
Harada S; Yalamanchili R; Kieff E
J Virol; 1998 Dec; 72(12):9948-54. PubMed ID: 9811732
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells.
Cuomo L; Trivedi P; de Grazia U; Calogero A; D'Onofrio M; Yang W; Frati L; Faggioni A; Rymo L; Ragona G
J Med Virol; 1998 Jul; 55(3):219-26. PubMed ID: 9624610
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter.
Jiménez-Ramírez C; Brooks AJ; Forshell LP; Yakimchuk K; Zhao B; Fulgham TZ; Sample CE
J Virol; 2006 Nov; 80(22):11200-8. PubMed ID: 16956945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
